Publicaciones en colaboración con investigadores/as de Hospital Universitari de Girona Dr. Josep Trueta (26)

2024

  1. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

2023

  1. Association of Serum Neurofilament Light Chain Levels at Disease Onset with Disability Worsening in Patients with a First Demyelinating Multiple Sclerosis Event Not Treated with High-Efficacy Drugs

    JAMA Neurology, Vol. 80, Núm. 4, pp. 397-403

  2. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  3. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  4. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  2. Gadolinium-enhanced brain lesions in multiple sclerosis relapse

    Neurologia, Vol. 37, Núm. 7, pp. 557-563

  3. Recommendations for the diagnosis and treatment of multiple sclerosis relapses

    Journal of Personalized Medicine, Vol. 12, Núm. 1

2021

  1. Direct costs of relapses in patients with relapsing-remitting multiple sclerosis

    Neurology Perspectives, Vol. 1, Núm. 3, pp. 160-169

2019

  1. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial

    European Journal of Neurology, Vol. 26, Núm. 3, pp. 525-532

  2. Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479

  3. Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441

2018

  1. Review of the novelties from the 2017 ECTRIMS congress, presented at the 10th post-ectrims meeting (I)

    Revista de Neurologia, Vol. 67, Núm. 1, pp. 15-27

  2. Review of the novelties from the 2017 ectrims congress, presented at the 10th post-ectrims meeting (II)

    Revista de Neurologia, Vol. 67, Núm. 2, pp. 50-62

2016

  1. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses

    Multiple Sclerosis, Vol. 22, Núm. 1, pp. 117-121

  2. Long-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis

    PLoS ONE, Vol. 11, Núm. 8

  3. Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS

    Revista de Neurologia, Vol. 62, Núm. 12, pp. 559-569

2015

  1. Review of the novelties from the 2014 ECTRIMS-ACTRIMS joint congress, presented at the 7th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 61, Núm. 6, pp. 271-283

  2. Review of the novelties from the 2014 ectrims-actrims joint congress, presented at the 7th post-ectrims meeting (i)

    Revista de Neurologia, Vol. 61, Núm. 5, pp. 215-224

2014

  1. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)

    Revista de Neurologia, Vol. 59, Núm. 7, pp. 307-316